Byoung Chul Cho, MD, PhD, discussed findings from cohort C of the CHYRSALIS-2 study exploring amivantamab plus lazertinib in patients with non–small cell lung cancer with uncommon EGFR mutations. A ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/azitra-inc-announces-q3-2024-financial-results-and-provides-business-updates ...

ATR-04 is in development for EGFR inhibitor ("EGFRi") associated rash, which is caused by the suppression of skin immunity by EGFRis and subsequent inflammation and often elevated levels of IL ...

Pipeline and Anticipated Milestones Q1 2025: Initial safety data from first set of Netherton syndrome patients in the Phase 1b trial Q1 2025: First patient dosed with ATR-04 for EGFRi rash in a Phase ...

Paronychia is a type of nail infection, most commonly caused by the bacteria called Staphylococcus aureus, which affects the skin around the nail (called nail folds). It can also occur as a result of ...

Pipeline and Anticipated Milestones Q1 2025: Initial safety data from first set of Netherton syndrome patients in the Phase 1b trial Q1 2025: First patient dosed with ATR-04 for EGFRi rash in a ...

SymphonyAI, a leader in predictive and generative AI SaaS products for the enterprise, announced today that industry luminary Ravi Narula has joined the company as chief financial officer. With a ...

has granted Fast Track Designation for topically applied ATR-04 to treat moderate to severe Epidermal Growth Factor Receptor inhibitor (EGFRi) associated dermal toxicity. BRANFORD, Conn., ...